中药辅助卡瑞利珠单抗联合白蛋白紫杉醇三线及以上方案治疗晚期非小细胞肺癌的临床研究  

Efficacy of Traditional Chinese Medicine-assisted Camrelizumab Combined with Albumin-Bound Paclitaxel as Third-or Later-line Regimen for the Treatment of Advanced Non-Small Cell Lung Cancer

作　　者：彭喜娜 白倩 皇甫乐双 PENG Xina;BAI Qian;HUANGFU Leshuang(Nanyang Traditional Chinese Medicine Hospital,Nanyang,473000)

机构地区：[1]河南省南阳市中医院,473000 [2]河南省南阳市唐河县中医院,473400

出　　处：《实用癌症杂志》2025年第1期142-146,共5页The Practical Journal of Cancer

摘　　要：目的探究中药辅助卡瑞利珠单抗联合白蛋白紫杉醇三线及以上方案治疗晚期NSCLC的应用效果。方法回顾性选取临床二线治疗失败的晚期NSCLC病例,均行卡瑞利珠单抗联合白蛋白紫杉醇三线及以上方案治疗,根据是否行中药辅助治疗,分为中药辅助治疗组和非中药辅助治疗组。比较两组客观反应率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)和总生存期(OS),生存资料采用Kaplan-Meier法进行分析,并采用log-rank检验。根据不良事件通用术语标准(CTCAE 4.03)评估不良反应的发生情况。结果120例晚期NSCLC患者,其中63例仅行卡瑞利珠单抗联合白蛋白紫杉醇三线及以上方案治疗,57例还接受了中药辅助治疗。中药辅助治疗组和非中药辅助治疗组ORR分别为59.65%和47.62%(χ^(2)=1.740,P=0.187),DCR分别为77.19%和61.90%(χ^(2)=11.072,P=0.001)。中药辅助治疗组中位PFS(5.27个月vs.3.57个月,P=0.0074)和中位OS(7.09个月vs.6.47个月,P=0.043)均显著高于非中药辅助治疗组。结论中药辅助卡瑞利珠单抗联合白蛋白紫杉醇三线及以上方案的治疗方式可显著延长晚期NSCLC患者的PFS和OS。Objective To explore the application effect of traditional chinese medicine-assisted camrelizumab combined with albumin-bound paclitaxel as third-or later-line regimen in the treatment of advanced non-small cell lung cancer.Methods The present study retrospectively selected cases with advanced NSCLC who failed second line treatment.All cases were treated with camrelizumab combined with albumin paclitaxel 3 line or above scheme,and were divided into chinese medicine auxiliary treatment group and non chinese medicine auxiliary treatment group according to whether to take chinese medicine auxiliary treatment or not.Short-term and long-term efficacy were evaluated through ORR,DCR,PFS,and OS.Survival data were analyzed using Kaplan Meier method and log rank test.Evaluate the occurrence of side effects according to the Common Terminology Standard for Adverse Events(CTCAE 4.03).Results A total of 120 cases with advanced NSCLC were included in this study,of which 63 patients only received Camrelizumab combined with albumin paclitaxel three line and above treatment,and 57 patients received additional Chinese medicine adjuvant treatment.The ORR of the traditional Chinese medicine assisted treatment group and the non traditional Chinese medicine assisted treatment group were 59.65%nd 47.62%,respectively(χ^(2)=1.740,P=0.187),with DCR of 77.19%and 61.90%,respectively(χ^(2)=11.072,P=0.001).The median PFS(5.27 months vs.3.57 months,P=0.0074)and median OS(7.09 months vs.6.47 months,P=0.043)in the adjuvant therapy group of chinese medicine were significantly higher than those in the non-adjuvant therapy group.Conclusion The PFS and OS of cases with advanced NSCLC can be significantly prolonged by the combination of Chinese medicine with Camrelizumab and albumin paclitaxel.

关 键 词：晚期非小细胞癌 中药辅助治疗 生存期 

分 类 号：R734.2[医药卫生—肿瘤]